Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack

August 27, 2012, Brigham and Women's Hospital

According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet.

For more than a million Americans who survive a heart attack each year, doctors routinely prescribe a daily aspirin to help prevent the formation of in the arteries which can frequently lead to another heart attack. Other platelet blockers, like , which also serve this purpose, are often added for up to a year, but the scientific evidence is unclear about whether adding platelet blockers to aspirin beyond this timeframe is clinically useful. Despite such therapies, these patients have an almost 15 percent chance of having another atherosclerosis-related event that brings them to the hospital within a year.

"There continues to be substantial uncertainty regarding the benefit of long-term in addition to aspirin in patients with prior heart attacks," said Benjamin M. Scirica, M.D., M.P.H., investigator at the TIMI Study Group, a cardiologist at BWH, and one of the study's investigators. "This is the first study to show convincingly that continued, long-term, therapy beyond one year with more potent antiplatelet therapy reduces the risk of having another cardiovascular event." Previous studies in did not show this benefit.

Researchers from the TIMI Study Group at BWH have shown, for the first time, that adding vorapaxar, a new antiplatelet medication, on top of standard therapy which includes aspirin, is effective for long-term secondary prevention in with a prior heart attack. When used with aspirin and other standard antiplatelet therapy in a broad group of patients with previous heart attack, vorapaxar reduced the risk of cardiovascular death, heart attack or stroke by an additional 20 percent.

This randomized, double blind, placebo-controlled, multinational study followed 26,449 patients for more than two years while receiving standard antiplatelet therapy for established atherosclerosis, including previous heart attack, stroke or atherosclerotic narrowing in the arteries of the legs. Participants were randomly assigned to receive the investigational platelet blocker (2.5 mg orally once daily) with standard therapy, or a placebo with standard therapy. The overall trial results, which were presented and published in March 2012, demonstrated a 13 percent reduction in the risk of cardiovascular death, heart attack or stroke. These new findings focus specifically on the 17,779 patients with a prior heart attack.

Vorapaxar is the first of a new class of investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonists. Unlike other antithrombotic drugs, vorapaxar blocks thrombin from stimulating platelets to stick together and create clots. In addition to the benefit of reducing future cardiac events, researchers also report that this new therapy was found to increase the risk of moderate or severe bleeding in patients with prior heart attacks. Intracranial hemorrhage tended to be higher but did not differ significantly between vorapaxar than placebo (0.6 vs. 0.4 percent at 3 years),

Researchers caution that if vorapaxar becomes available for clinical use, clinicians will have to balance the antithrombotic efficacy versus the risk of bleeding for the individual patient.

"Of the groups we studied, the greatest net was observed in those patients who are less than 75 years old, have no history of stroke or transient ischemic attacks, and weigh at least 60 kilograms," said Scirica. "In this group of 14,909 patients, 84 percent of the group with prior heart attacks, vorapaxar reduced the risk of cardiovascular death, , or stroke by 25 percent and cardiovascular death alone by 27 percent."

Explore further: New class of platelet blockers proves effective in phase III trial

Related Stories

New class of platelet blockers proves effective in phase III trial

March 26, 2012
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...

Merck blood thinner shows mixed results: study

March 24, 2012
An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.

New platelet blocker reduces blood clots, artery-opening procedures

June 21, 2012
A new investigational platelet blocker reduces the rate of clotted arteries and the need for artery-opening revascularization procedures in the legs in people with peripheral artery disease (PAD), according to new research ...

Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks

September 26, 2011
Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of ...

Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events

March 26, 2012
Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall ...

Recommended for you

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

Place of residence linked to heart failure risk

January 9, 2018
Location. Location. Location.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.